quantum mesf kits fcsc827b (Bangs Laboratories)
90
Structured Review
Bangs Laboratories
quantum mesf kits fcsc827b
Quantum Mesf Kits Fcsc827b, supplied by Bangs Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantum+mesf+kits+fcsc827b/quantum+mesf+kits+fcsc827b/pm36683161-254-2-11
Average 90 stars, based on 1 article reviews
Quantum Mesf Kits Fcsc827b, supplied by Bangs Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantum+mesf+kits+fcsc827b/quantum+mesf+kits+fcsc827b/pm36683161-254-2-11
Average 90 stars, based on 1 article reviews
quantum mesf kits fcsc827b - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Cell Surface Receptor Assay:Article Title: Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. Article Snippet: Antibody-based therapies could be led astray when target receptors are expressed on nontarget sites, and the on-target toxicity poses critical challenges to clinical applications.. Here, a biomimetic indirect active targeting (INTACT) strategy is proposed based on receptor expression disparities between nontarget sites and the targets.. By prebinding the antibodies using cell membrane vesicles with appropriate receptor expressions, the INTACT strategy could filter out the interactions on nontarget sites due to their inferior receptor expression, whereas ensure on-demand release at the targets by competitive binding. Expressing:Article Title: Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. Article Snippet: Antibody-based therapies could be led astray when target receptors are expressed on nontarget sites, and the on-target toxicity poses critical challenges to clinical applications.. Here, a biomimetic indirect active targeting (INTACT) strategy is proposed based on receptor expression disparities between nontarget sites and the targets.. By prebinding the antibodies using cell membrane vesicles with appropriate receptor expressions, the INTACT strategy could filter out the interactions on nontarget sites due to their inferior receptor expression, whereas ensure on-demand release at the targets by competitive binding. Labeling:Article Title: Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. Article Snippet: Antibody-based therapies could be led astray when target receptors are expressed on nontarget sites, and the on-target toxicity poses critical challenges to clinical applications.. Here, a biomimetic indirect active targeting (INTACT) strategy is proposed based on receptor expression disparities between nontarget sites and the targets.. By prebinding the antibodies using cell membrane vesicles with appropriate receptor expressions, the INTACT strategy could filter out the interactions on nontarget sites due to their inferior receptor expression, whereas ensure on-demand release at the targets by competitive binding. Article Title: Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy Article Snippet: For WB analysis, the proteins on SDS‐PAGE were transferred to PVDF membrane with transfer buffer (Invitrogen, CA, USA), and stained with antibodies against EpCAM (abs‐120056, absin), antibodies against E‐cadherin (bs‐1519R, Bioss), antibodies against ATPase Na + /K + beta 2 (bs‐23413R, Bioss), CD47 antibody (bs‐2386R, Bioss), and HRP‐labeled goat anti‐rabbit IgG (bs‐40295G‐HRP, Bioss) as the secondary antibodies. .. Fluorescence:Article Title: Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. Article Snippet: Antibody-based therapies could be led astray when target receptors are expressed on nontarget sites, and the on-target toxicity poses critical challenges to clinical applications.. Here, a biomimetic indirect active targeting (INTACT) strategy is proposed based on receptor expression disparities between nontarget sites and the targets.. By prebinding the antibodies using cell membrane vesicles with appropriate receptor expressions, the INTACT strategy could filter out the interactions on nontarget sites due to their inferior receptor expression, whereas ensure on-demand release at the targets by competitive binding. Article Title: Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy Article Snippet: For WB analysis, the proteins on SDS‐PAGE were transferred to PVDF membrane with transfer buffer (Invitrogen, CA, USA), and stained with antibodies against EpCAM (abs‐120056, absin), antibodies against E‐cadherin (bs‐1519R, Bioss), antibodies against ATPase Na + /K + beta 2 (bs‐23413R, Bioss), CD47 antibody (bs‐2386R, Bioss), and HRP‐labeled goat anti‐rabbit IgG (bs‐40295G‐HRP, Bioss) as the secondary antibodies. .. |